EN DE

Centrum Medyczne ENEL-MED S.A (ENE) Fair Value & Analysis

Healthcare · PL · Market cap 537M PLN

CM Centrum Medyczne ENEL-MED S.A ENE · WAR
Price20.20 PLN
Fair Value7.75 PLN
Upside-61.6%
Quality50/100
Watch Centrum Medyczne ENEL-MED S.A for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 0.9% net margin
Low debt · generates free cash flow
Trails peers (5/13)
Narrow moat 32/100
Evidence: High Range 7.52 PLN – 9.69 PLN Share as image

Fair value as of: Jul 18, 2026

From 26 valuation models · updated 23 days ago

Share price +5.2% over the past month.

A solid business, but screening 62% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (9.69 PLN). The favourable scenario is already priced in.
  • Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

27.60 PLN 12.80 PLN Fair Value 7.75 PLN Jul 2020 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.

How to read this chart

60‑month range 12.80 PLN – 27.60 PLN · fair‑value band 7.52 PLN – 9.69 PLN · the 20.20 PLN price screens above the 7.75 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Centrum Medyczne ENEL-MED S.A (ENE) currently trades at 20.20 PLN, while our model-based Fair Value estimate is 7.75 PLN, implying the stock looks roughly 61.6% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Centrum Medyczne ENEL-MED S.A generated revenue of 854M PLN at a net margin of 1.5%. Revenue grew 17.5% year over year. It earns a return on equity of 7.2%. Net debt stands at 308M PLN. Fundamentals as of Jul 18, 2026

Our scenario range runs from 7.52 PLN (bear case) to 9.69 PLN (bull case); at 20.20 PLN, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 20% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -62%, ENE screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 12.84 PLN 21.02 PLN 33.25 PLN 80
Residual Income 4.98 PLN 5.08 PLN 5.02 PLN 76
Rev-Margin DCF 9.50 PLN 15.38 PLN 23.30 PLN 74
All 26 models by family
DCF Models
FCF DCF 13.15 PLN 22.78 PLN 38.33 PLN 38
Owner Earnings 7.24 PLN 12.34 PLN 20.57 PLN 31
5Y Revenue Exit 9.50 PLN 15.46 PLN 23.51 PLN 39
5Y EBITDA Exit 27.76 PLN 54.52 PLN 89.52 PLN 41
5Y P/E Exit 9.55 PLN 15.58 PLN 22.52 PLN 38
10Y Revenue Exit 10.51 PLN 16.46 PLN 25.59 PLN 36
10Y EBITDA Exit 21.97 PLN 43.18 PLN 77.93 PLN 37
10Y P/E Exit 10.75 PLN 16.54 PLN 24.80 PLN 35
Earnings-Based
Graham-Dodd 3.10 PLN 16.31 PLN 22.58 PLN 54
Lynch FV 4.48 PLN 6.40 PLN 8.33 PLN 50
PEG = 1.0 4.48 PLN 6.40 PLN 8.33 PLN 46
EPV 5.72 PLN 6.42 PLN 7.00 PLN 59
Dividend Discount
Gordon GGM 0.6500 PLN 1.17 PLN 1.61 PLN 70
DDM Multi-Stage 0.6500 PLN 1.07 PLN 1.25 PLN 61
Multiples
P/E Multiple 7.52 PLN 10.03 PLN 12.54 PLN 63
P/S Multiple 5.81 PLN 7.75 PLN 9.69 PLN 58
P/B Multiple 5.81 PLN 7.75 PLN 9.69 PLN 55
EV/EBIT 10.30 PLN 13.54 PLN 16.78 PLN 53
EV/EBITDA 38.90 PLN 51.67 PLN 64.44 PLN 54
EV/Revenue 7.52 PLN 10.50 PLN 13.47 PLN 43
Asset-Based
NCAV (Graham) 3.29 PLN 4.40 PLN 6.57 PLN 50
Growth DCF
Growth DCF 12.84 PLN 21.02 PLN 33.25 PLN 80
Rev-Margin DCF 9.50 PLN 15.38 PLN 23.30 PLN 74
Economic Profit
Residual Income 4.98 PLN 5.08 PLN 5.02 PLN 76
ROIC Compounder 5.72 PLN 6.42 PLN 7.55 PLN 72
Growth Earnings
Growth-Adj P/E 6.83 PLN 9.75 PLN 12.68 PLN 68

Widest divergence: DCF Models (16.46 PLN) versus Dividend Discount (1.07 PLN). Highest evidence: Growth DCF (80).

Notify me when ENE reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 854M PLN
Revenue growth (YoY) +17.5%
Net margin 1.5%
Return on equity 7.2%
Free cash flow 32.0M PLN FY2025
P/E ratio 70.4
More key figures
Operating margin 1.5%
EPS (TTM) 0.2700 PLN
EPS growth (YoY) -42.2%
Net debt 308M PLN FY2025

Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 50/100

Of which business quality 50 · Market factors (momentum, volatility) 47

Profitability 41
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 45
Earnings quality: real cash, not paper profit
Fin. Strength 43
Balance sheet, leverage, solvency risk
Investment 52
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 41
Price trend over the last 3–12 months (market factor)
52W Momentum 33
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Centrum Medyczne ENEL-MED S.A., together with its subsidiaries, operates hospitals in Poland, Austria, France, the United Kingdom, and internationally.

Full company description

Centrum Medyczne ENEL-MED S.A., together with its subsidiaries, operates hospitals in Poland, Austria, France, the United Kingdom, and internationally. It offers various medical services comprising pediatric specialist consultations, dentistry, orthopedic, infertility treatment, rehabilitation, psychological, imaging and diagnostics, laboratory diagnostics, and emergency care services. The company also provides vaccination services for adult and children. Centrum Medyczne ENEL-MED S.A. was founded in 1993 and is headquartered in Warsaw, Poland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Centrum Medyczne ENEL-MED S.A reported revenue of 854M PLN in FY2025 versus 441M PLN in FY2021, a compound +18.0%/yr. Reported net income was 12.9M PLN in FY2025.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
854M PLN
Latest YoY
+16.1%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+20.0%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.4%
Avg. growth/yr (15Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.9%
Revenue +18.0%/yr
FY21 441M PLN
FY22 495M PLN
FY23 619M PLN
FY24 736M PLN
FY25 854M PLN
Net income
FY21 −1.4M PLN
FY22 −23.6M PLN
FY23 8.2M PLN
FY24 14.6M PLN
FY25 12.9M PLN
Character of growth · EPS growth decomposed (2014-2025) −4.2 % p.a.
Revenue per share +11.0 pp

of which total revenue +13.2 pp · buybacks/dilution −2.3 pp

EBIT margin −10.4 pp
Tax rate −2.0 pp
Residual (interest, one-offs) −2.7 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

ENE screens 62% overvalued. Compare with HCA Healthcare, Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Centrum Medyczne ENEL-MED S.A · Fair Value
7.75 PLN −62%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Centrum Medyczne ENEL-MED S.A Fair Value". https://www.fairvalue-calculator.com/stock/ENE

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 50 · Below median
Fair Value upside −62% · Bottom 25%
Return on equity (TTM) 4% · Below median
Return on assets 3% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 3% · Below median
Revenue growth 15% · Above median
Debt / equity 0.09× · Lower than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 70.4× · Pricier than 75% of peers
P/B 0.78× · Cheaper than 75% of peers
P/S (TTM) 0.16× · Cheaper than 75% of peers
P/FCF 4.5× · Pricier than median
EV/EBITDA 2.6× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 23
FUTURE 76 · sector 24
PAST 17 · sector 30
HEALTH 95 · sector 90
DIVIDEND 0 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Centrum Medyczne ENEL-MED S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Centrum Medyczne ENEL-MED S.A (ENE) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of 7.75 PLN versus a price of 20.20 PLN, about −62% (overvalued).
What is the fair value of ENE?
Our model-based fair value for Centrum Medyczne ENEL-MED S.A is 7.75 PLN (as of Jul 18, 2026), built from audited fundamentals. The current price is 20.20 PLN.
What is the quality score of ENE?
Centrum Medyczne ENEL-MED S.A has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Centrum Medyczne ENEL-MED S.A (ENE)?
Centrum Medyczne ENEL-MED S.A reported trailing-twelve-month revenue of about 854M PLN (latest available figure, as of Jul 18, 2026).
What is the net profit margin of ENE?
The net profit margin of Centrum Medyczne ENEL-MED S.A is about 1.5%, meaning it keeps roughly 1.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Centrum Medyczne ENEL-MED S.A and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.